Browse the evidence

Linoleic acid has a long half-life in the body (approximately two years), meaning that reducing intake takes years to significantly lower tissue levels.

Be patient when reducing seed oils. It can take up to six years to significantly replace body stores of linoleic acid with healthier fats.

Intermittent Energy Restriction (IER), including intermittent fasting and time-restricted eating, does not provide clear incremental benefit over Continuous Energy Restriction (CER) for weight loss or cardiometabolic health in humans.

Intermittent fasting or time-restricted eating is not superior to simply eating fewer calories every day for weight loss or heart health. If you prefer fasting, it may help you restrict calories, but it offers no extra metabolic benefit over consistent daily calorie control. Choose the approach that fits your lifestyle and allows you to maintain a healthy diet.

Intensive lifestyle intervention (ILI) increases the risk of frailty fractures and negatively impacts bone mineral density and lean body mass in adults with overweight/obesity and type 2 diabetes.

Be aware that significant weight loss can lead to some loss of bone density and a higher risk of fractures. Discuss strategies to protect your bones, such as ensuring adequate calcium/vitamin D intake and incorporating resistance training, with your healthcare provider while pursuing weight loss.

There is no conclusive evidence that varying the relative quantities of dietary carbohydrates and fats (macronutrient partitioning) significantly affects the degree of weight loss or the duration of weight maintenance beyond the effects of total caloric intake.

Do not expect a specific macronutrient ratio (low-carb vs. low-fat) to give you a metabolic advantage for long-term weight loss if you are eating the same number of calories. The science shows that both diets work equally well for weight maintenance when calories are matched. Focus on finding a diet you can adhere to long-term, as compliance is the primary driver of success, not the specific ratio of carbs to fats.

Intensive lifestyle interventions (diet and exercise) alone do not significantly reduce cardiovascular event risk in overweight/obese adults with type 2 diabetes compared to usual care, whereas weight loss achieved through metabolic surgery significantly reduces complications and mortality.

While healthy eating and exercise are important, they might not be enough to protect your heart if you have type 2 diabetes and are overweight. The Look AHEAD study showed that intensive lifestyle changes didn't lower heart attack or stroke risk compared to standard care. However, losing a significant amount of weight (10% or more) did help. For some, metabolic surgery offers the best chance to reduce complications and live longer. Talk to your doctor about combining lifestyle changes with medications or other treatments.

Longitudinal changes in body composition (fat mass, lean mass, or waist circumference) are not significantly associated with the risk of myocardial infarction (MI) in patients with type 2 diabetes.

In type 2 diabetes, losing weight and fat does not significantly reduce your risk of having a heart attack (myocardial infarction). However, it does significantly reduce your risk of heart failure. Therefore, weight loss remains crucial for heart health, but for different reasons than preventing heart attacks.

Metabolic adaptation (a reduction in resting metabolic rate beyond what is predicted by body composition changes) is minimal, transient, and does not predict long-term weight regain in overweight women following weight loss.

Do not blame persistent weight regain on a 'slowed metabolism' or 'adaptive thermogenesis.' While your metabolism does drop slightly when you lose weight, this effect is small, temporary, and does not predict who will regain weight. Focus on sustainable lifestyle changes and long-term support rather than trying to 'trick' your metabolism.

In advanced CKD and dialysis patients, higher BMI (including morbid obesity) is associated with better survival outcomes, a phenomenon known as the 'obesity paradox'.

If you are on dialysis, do not try to lose weight. Your higher body weight is actually protecting your life. Focus on eating enough protein and calories to maintain your muscle mass, as losing weight is dangerous for dialysis patients.

Metabolic surgery, which yields approximately 25% weight loss at 10 years, is associated with a 44% lower risk of invasive cancer compared to non-surgical patients.

For individuals with severe obesity, metabolic surgery can lead to significant weight loss and a substantially lower risk of invasive cancer. Discuss with your doctor if you are a candidate.

Anthropometric measures (BMI, waist circumference, waist-to-hip ratio) are recommended as feasible, cost-effective core measures for obesity clinical trials, despite being less accurate than imaging methods like DXA or MRI.

For obesity research, simple measurements like height, weight, and waist circumference are the standard starting point because they are feasible and cost-effective. While they are less precise than advanced imaging, they are sufficient for tracking general trends in body composition across large groups.

Current energy intake recommendations for pregnant women with obesity overestimate total daily energy expenditure (TDEE), potentially promoting excess gestational weight gain.

Standard calorie recommendations for pregnant women with obesity are likely too high. This study suggests that following these standard guidelines may lead to excessive weight gain because they overestimate how many calories these women actually burn. Healthcare providers should consider lower energy targets or more personalized metabolic assessments for obese pregnant women to prevent excess gestational weight gain.

Housing mice at thermoneutrality (30°C) rather than standard room temperature (22°C) does not improve the prediction of human drug efficacy for weight loss, as the direction and magnitude of drug effects vary by mechanism regardless of temperature.

This paper is a methodological critique for preclinical researchers, not a direct guide for human behavior. It suggests that while standard mouse housing (22°C) creates thermal stress, simply moving to thermoneutrality (30°C) does not solve the translatability problem for obesity drugs. Researchers should test drugs at both temperatures to understand mechanism-specific responses, as efficacy can flip depending on the thermal environment.

GLP-1 receptor agonists (like semaglutide) and hFGF21 analogs produce similar weight loss efficacy in mice regardless of whether they are housed at standard room temperature (22°C) or thermoneutrality (30°C).

For GLP-1 and hFGF21 drugs, the mouse model's housing temperature is less critical for predicting efficacy magnitude than for other drug classes. These drugs work robustly in both cold-stressed and thermoneutral environments.

GDF15 analogs are significantly more effective at inducing weight loss in mice housed at standard room temperature (22°C) compared to thermoneutrality (30°C), with efficacy dropping by half at higher temperatures.

If developing GDF15-based therapies, preclinical data from cold-housed mice may overestimate efficacy compared to thermoneutral conditions. The drug's effectiveness is halved when mice are not cold-stressed.

Peptide YY (PYY) analogs show greater weight loss efficacy in mice housed at thermoneutrality (30°C) compared to standard room temperature (22°C), contrary to the trend seen with GDF15.

For PYY-based therapies, preclinical data from thermoneutral mice may better reflect potential efficacy than data from cold-stressed mice, where the drug appears largely ineffective.

Bariatric surgery significantly reduces all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACE) compared to medical therapy in patients with severe obesity and Type 2 Diabetes.

For severe obesity and Type 2 Diabetes, bariatric surgery is the most effective treatment for reducing heart disease risk and death. It significantly lowers the risk of heart attack, stroke, and heart failure compared to medical therapy alone. Discuss surgical options with a specialist if lifestyle changes and medications are insufficient.

Bariatric surgery significantly reduces the risk of developing heart failure and improves mortality in patients with existing heart failure and obesity.

For severe obesity, bariatric surgery is a highly effective treatment that can prevent heart failure and significantly improve survival in those who already have it. It is safe and can even be used as a bridge to heart transplantation in severe cases. Consult with a bariatric surgeon and cardiologist to see if you are a candidate.

The reduction in schizophrenia risk associated with GLP-1 receptor agonists is mediated by body mass index (BMI) rather than glycemic control.

The mental health benefits of GLP-1 drugs for schizophrenia risk appear to come from weight loss, not from lowering blood sugar. This means that interventions focusing on weight management (whether through GLP-1 drugs or other means) may be the key to reducing this specific psychiatric risk. It highlights the importance of addressing obesity in mental health prevention strategies.

Overweight status (BMI 25-<30) is not associated with increased risk for most cardiovascular outcomes and may have a neutral or slightly protective effect on all-cause mortality compared to normal weight.

Being overweight is not as strongly linked to heart disease or death as obesity. While weight management is still beneficial, the urgency is lower for overweight individuals compared to those with obesity. Focus on overall health metrics rather than just weight.

Chronic nutrient overload and sedentary behavior lead to 'oxidative distress' (excessive ROS), which causes insulin resistance in skeletal muscle by activating stress kinases (JNK, p38 MAPK) that inhibit insulin signaling.

Insulin resistance in skeletal muscle often starts with chronic nutrient overload, not just sugar. When you consistently consume more energy than you burn, it creates 'oxidative distress' that blocks insulin signals. Managing total energy balance and activity levels is critical to preventing this specific type of metabolic damage.

SGLT2 inhibitors improve mitochondrial function and reduce oxidative stress, contributing to their cardioprotective and renoprotective effects.

SGLT2 inhibitors may help your cells produce energy more efficiently and reduce cellular stress, which protects your heart and kidneys. This is part of why these drugs work beyond just lowering blood sugar.

Bone Mineral Content (BMC) continues to decline during the weight regain phase (6-12 months) even when total body weight and fat mass are increasing.

If you lose a significant amount of weight (5% or more), your bone density may drop. This drop can continue even if you regain some of the weight later. To protect your bones, consider baseline bone density assessments if you are at risk (e.g., postmenopausal women) and ensure adequate calcium and vitamin D intake alongside resistance training.

Standard questionnaires (7dPAR, BWHS) and prediction equations (DRI, BOD POD) are valid for estimating Total Energy Expenditure (TEE) at a group level but lack sufficient accuracy for individual assessment due to wide limits of agreement and low correlation with the gold standard (DLW).

Use questionnaires and standard equations to estimate your energy needs for general planning or group studies, but do not rely on them for precise individual calorie targets. The error margin is too large (potentially ±1000+ kcal) for effective individual weight management. For individual precision, more rigorous testing or metabolic assessment is required.

Maxillomandibular advancement (MMA) surgery achieves the largest and most durable reductions in OSA severity, with efficacy comparable to CPAP.

If you have severe sleep apnea and cannot use CPAP, ask about Maxillomandibular Advancement (MMA) surgery. It is a major surgery but can provide a permanent, CPAP-level reduction in apnea events for the right candidate.